Poor glycemic control is associated with an increased risk for low-trauma fracture in people with type 1, but not type 2, diabetes, study findings indicate.
Research based on insurance claims data indicates that new users of the sodium-glucose cotransporter-2 inhibitor canagliflozin are no more likely to experience a fracture than new users of glucagon-like peptide-1 receptor agonists.